Zynquista：Zynquista (sotagliflozin)
Zynquista (sotagliflozin)
2024年7月23日—Zynquista(sotagliflozin)isadualsodium-glucoseco-transporter-1and-2inhibitorindevelopmentasanadjuncttoinsulintherapyfor ...。其他文章還包含有：「Zynquista」、「FDA拒絕賽諾菲1型糖尿病藥物Zynquista新藥批准」、「Zynquista」、「LexiconprepsFDAresubmissionfordiabeteshopeful...」、「LexiconplansanotherbidforZynquistaintype1diabetes」、「Sotagliflozin」、「Sotagliflozin」、「賽諾菲口服糖...
查看更多 離開網站
Zynquista
https://www.ema.europa.eu
Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ? 27 ...
FDA拒絕賽諾菲1型糖尿病藥物Zynquista新藥批准
https://news.gbimonthly.com
Zynquista是葡萄糖蛋白質通道SGLT-1和SGLT-2的口服雙重抑製劑，這些蛋白質影響腸道和腎中的葡萄糖吸收。本次NDA基於...
Zynquista
https://www.ema.europa.eu
Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ...
Lexicon preps FDA resubmission for diabetes hopeful ...
https://www.fiercepharma.com
Lexicon is hoping for an approval that clears the drug to be used as an add-on to insulin therapy for adults with Type 1 diabetes mellitus and ...
Lexicon plans another bid for Zynquista in type 1 diabetes
https://www.pharmaceutical-tec
Lexicon's Zynquista (sotagliflozin) is an oral dual inhibitor of the sodium-dependent glucose co-transporter types 1 and 2 (SGLT1 and SGLT2).
Sotagliflozin
https://pubmed.ncbi.nlm.nih.go
Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials ...
Sotagliflozin
https://en.wikipedia.org
Sotagliflozin was approved for medical use in the European Union in April 2019, as Zynquista, for the treatment for type 1 diabetes, and in the United States in ...
賽諾菲口服糖尿病藥物sotagliflozin上市申請被美國FDA拒絕
https://ibmi.taiwan-healthcare
3月23日，賽諾菲與合作夥伴Lexicon宣佈其SGLT1/2雙抑制劑sotagliflozin（商品名Zynquista）用於治療成人一型糖尿病的上市申請被美國FDA拒絕，但具體原因 ...
Sotagliflozin
https://pubmed.ncbi.nlm.nih.go
Sotagliflozin (Zynquista™) is a dual inhibitor of sodium-glucose co-transporters (SGLT) 1 and 2 being developed by Lexicon Pharmaceuticals and Sanofi as a ...